Stockreport

Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

AIMMUNE THERAPEUTICS  (AIMT) 
Last aimmune therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.aimmune.com/corporate-profile
PDF — Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulator [Read more]